FDA
31st May 2013

Welcome to the Innovative Science Solutions FDA Advisory Committee Blog!

Innovative Science Solutions (ISS), world-renowned for its FDA AdComm support expertise, is thrilled to announce that we are launching.

Welcome to the Innovative Science Solutions FDA Advisory Committee Blog!

Millions of dollars could be riding on the outcome of an FDA Drugs Advisory Committee (AdComm) review meeting. Any misstep could affect drug approval likelihood and timing.

So what’s a company to do? Be prepared.

Innovative Science Solutions (ISS), world-renowned for its FDA AdComm support expertise, is thrilled to announce that we are launching a new blog designed specifically to deliver the information you need to be up-to-date on drug-related FDA AdComms.

Information we’ll be posting on a regular basis includes:

  • AdComm Meeting Updates: Real-time announcements of upcoming drug-related FDA AdComm meetings, direct links to briefing materials as soon as they are posted, meeting outcomes and commentary.
  • AdComm Roll Call: Monthly updates with the latest changes to the drug-related FDA AdComms, including pertinent biographical information on those new members.
  • Hot Topics in AdComms: When it comes to industry headline news that you need to know, we’ll make sure to post about it here. Don’t miss the latest in FDA AdComms!
  • Quarterly Giveaways: Each quarter we’ll post free downloads of useful AdComm preparation materials!

With this blog, ISS hopes to provide you with comprehensive AdComm information, insights that you won’t find elsewhere, and unique AdComm preparation tools. Subscribe today!

 

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us